Cardio Diagnostics Holdings, Inc. (CDIO) - Cumulative Company Assets

Cardio Diagnostics is implementing cloud-based neural networks for genetic map decoding, transforming laboratory diagnostics into a high-margin SaaS model. The firm's success relies on the demand for early ischemia detection, while total assets on the GURU.Markets price chart stand at 9.16. Cardio Diagnostics has achieved a breakthrough in epigenetics, enabling the prevention of cardiac catastrophes through a standard blood draw.

Leveraging its technological leadership in cardio-IT and epigenetics, Cardio Diagnostics (CDIO) is accumulating resources for expansion, as reflected in this calculation of property and resources, reverse-engineered via Return on Assets (ROA) to determine the aggregate of all assets and liabilities. Investors utilize this metric as an indicator of business scale, assessing the company's ability to convert its material base into innovative solutions for diagnosing cardiovascular risks.